The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Balancing immunotherapy efficiency and toxicity in lung cancer
Michel Obeid, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, comments on balancing toxicity and efficiency in immunotherapy, highlighting the need to identify the common immune profile between the two to decouple them. Some cytokines, such as IL-6, are shared between toxicities and efficiencies, and new anti-IL-6 treatments hold promise for decoupling these two concepts. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
